NASDAQ Most Volatile: American Capital (NASDAQ:ACAS), Chelsea Therapeutics International (NASDAQ:CHTP), Kandi Technologies Group (NASDAQ:KNDI), Zogenix (NASDAQ:ZGNX)

On April 14, 2014, American Capital, Ltd. (Nasdaq: ACAS) announced that it has committed $71 million to support the acquisition of Luminator Technology Group (“Luminator”) by Audax Group (“Audax”). Luminator is a leading designer and manufacturer of highly-engineered display, lighting and passenger communication systems for the global mass transportation market. Headquartered in Plano, TX, with additional operations in Denmark, Germany, Sweden, Brazil and Australia, Luminator serves OEMs and operators in the city bus, rail and aerospace markets worldwide. American Capital’s investment takes the form of a second lien term loan, committed delayed draw facility and common equity. American Capital Ltd. (NASDAQ:ACAS), shares after opening at $14.68 moved to $14.68 on last trade day and at the end of the day closed at $14.35. Company price to sales ratio in past twelve months was calculated as 7.95 and price to cash ratio as 12.29. American Capital Ltd. (NASDAQ:ACAS), showed a negative weekly performance of 4.78%.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) on Mar. 11 reported financial results for the fourth quarter and full year ended December 31, 2013. For the quarter ended Dec. 31, 2013, Chelsea reported a net loss of $5.3 million or ($0.07) per share versus a net loss of $2.2 million or ($0.03) per share for the same period in 2012. For the twelve months ended December 31, 2013, Chelsea reported a net loss of $16.4 million or ($0.24) per share compared to a net loss of $31.7 million of ($0.47) per share for the same period in 2012. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), shares fell 4.17% in last trading session and ended the day on $4.72. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), return on equity ratio is recorded as -62.20% and its return on assets is -55.80%. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), yearly performance is 170.98%.

On April 14, 2014, Kandi Technologies Group Inc (NASDAQ:KNDI), announced that Mr. Jing Ma, the Deputy Director of Electric Vehicles Development from the Shanghai Municipal Commission of Economic and Information Technology, Standing Committee member from Shanghai Jinshan District, along with the Vice Mayor of Jinshan District, Mr. Huadi Shen, and other government officials visited Kandi Electric Vehicles (Shanghai) Co., Ltd. (“Kandi Shanghai”) to finalize the plan to launch the Public EV Sharing System Pilot Project (the “Project”) in Jinshan District of Shanghai. Kandi Technologies Group Inc (NASDAQ:KNDI), shares moved down 0.82% in last trading session and was closed at $12.16, while trading in range of $ 11.80 – 13.38. Kandi Technologies Group Inc (NASDAQ:KNDI), year to date (YTD) performance is 3.14%.

Zogenix, Inc. (NASDAQ:ZGNX), won approval to sell the first painkiller made of pure hydrocodone as U.S. regulators recommended restrictions on popular combination treatments with the drug. The decision helped Zogenix shares climb the most in eight months. Zogenix, Inc. (NASDAQ:ZGNX), weekly performance is -0.41%. On last trading day company shares ended up $2.45. Zogenix, Inc. (NASDAQ:ZGNX), distance from 50-day simple moving average (SMA50) is -35.55%. Analysts mean target Price for the company is $5.73.